Jiangsu Alpha Pharmaceutical Co., Ltd.

Products

(1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol tetraacetate

    • Product Name: (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol tetraacetate
    • Chemical Name (IUPAC): (2R,3R,4R,5S,6R)-2-(acetyloxy)-6-[(4-chloro-3-{[4-[(oxolan-3-yl)oxy]benzyl}phenyl)methyl]oxy]-3,4,5-triacetyloxy-tetrahydro-2H-pyran-3,4,5-triyl triacetate
    • CAS No.: 864070-44-0
    • Chemical Formula: C34H37ClO10
    • Form/Physical State: Solid
    • Factroy Site: Yinchuan, Ningxia, China
    • Price Inquiry: sales8@bouling-chem.com
    • Manufacturer: Jiangsu Alpha Pharmaceutical Co., Ltd.
    • CONTACT NOW
    VTB
    Specifications
    HS Code 466151
    Iupac Name (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol tetraacetate
    Molecular Formula C33H37ClO11
    Molecular Weight 645.09 g/mol
    Cas Number 145783-15-9
    Appearance White to off-white powder
    Solubility Soluble in DMSO, methanol, and acetone
    Melting Point 178-182°C
    Storage Conditions Store at -20°C, protected from light
    Purity ≥98% (HPLC)
    Synonyms Ozagrel intermediate; Tetraacetate derivative
    Smiles CC(=O)OCC1C(C2=CC(=C(C=C2)CC3=CC=C(C=C3)OC4CCCO4)Cl)=OCC(C1OC(=O)C)OC(=O)C
    Boiling Point No data available, decomposes before boiling
    Usage Intermediate in pharmaceutical synthesis
    Density No data available

    As an accredited (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol tetraacetate factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing The chemical arrives in a 500 mg amber glass vial, sealed with a screw cap and labeled for laboratory use and safety.
    Container Loading (20′ FCL) Container Loading (20′ FCL) for (1S)-1,5-Anhydro…tetraacetate involves safe, moisture-protected, stable chemical packaging, maximizing space and transport security.
    Shipping This chemical, (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol tetraacetate, is shipped in tightly sealed containers under ambient or refrigerated conditions. Proper labeling and documentation ensure safety and regulatory compliance. Shipping adheres to all relevant hazardous material guidelines to prevent degradation or accidental exposure.
    Storage Store **(1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol tetraacetate** in a tightly closed container, protected from light and moisture. Keep at 2-8°C (refrigerated) in a well-ventilated area away from incompatible substances (strong acids, bases, and oxidizers). Ensure container is properly labeled and prevent unnecessary exposure. Handle under an inert atmosphere if required for stability.
    Shelf Life Shelf life: Typically stable for 2 years when stored in a cool, dry place, protected from light and moisture.
    Application of (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol tetraacetate

    Applications of (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol tetraacetate in Industrial Manufacturing

    Our material, (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol tetraacetate, serves as a crucial specialty intermediate across several advanced manufacturing verticals. As a direct producer, we ensure high consistency and compliance with international standards, supported by traceable quality management throughout all stages of production and technical support for client-specific end-use integration. Below, we detail the principal application sectors and key downstream conditions for the industrial adoption of this molecule.

    1. Antidiabetic Active Pharmaceutical Ingredient (API) Synthesis

    Pharmaceutical manufacturers utilize our molecule as a protected intermediate in the synthesis of SGLT2 inhibitor APIs for modern type 2 diabetes management therapies. The raw material enters advanced stepwise synthetic protocols, where its selective functional groups deliver high positional specificity in glycoside formation. Our product’s purity supports stringent impurity profiles demanded by finished drug certifications in regulated markets.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    2. API Process Impurity Reference Material Production

    Contract research and analytical laboratories employ our specialty intermediate to manufacture certified reference materials required for pharmacopoeial impurity profiling. Accurate synthetic replication of trace-level byproducts and process-related substances ensures regulatory submissions meet strict quantification and identification thresholds.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    3. Advanced Glycoside Intermediate Supply for Fine Chemical Synthesis

    Specialty fine chemical producers integrate our compound as a protected glycoside in multi-step syntheses for proprietary glucosylated structures, which act as building blocks for research, agrochemical, or diagnostic reagent development. Its defined stereochemistry and stable acetyl protection allow reliable downstream manipulation without risk of premature hydrolysis or rearrangement.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    4. Pharmaceutical Formulation Development—Analytical Proficiency Testing

    Analytical laboratories developing or validating SGLT2 inhibitor tablets and finished dosage forms include our highly defined intermediate as an external system suitability or spike-in recovery sample. Its physicochemical similarity to final APIs permits targeted evaluation of method specificity, system calibration, and formulation recovery accuracy in QC laboratory environments.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    Free Quote

    Competitive (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol tetraacetate prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please contact us at +8618005193850 or mail to sales8@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8618005193850

    Email: sales8@bouling-chem.com

    Inquiry

    Get Free Quote of Jiangsu Alpha Pharmaceutical Co., Ltd.

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    The Value and Characteristics of (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol tetraacetate

    Our day-to-day work revolves around making molecules like (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol tetraacetate from the ground up. This compound, with its intricate structure and functional groups, calls for a careful approach throughout synthesis and QA testing. Every batch requires constant vigilance — not just in maintaining purity, but also in understanding why certain specifications impact downstream applications. The people who request this product know it is not a stock item. Each lot’s journey—from raw feedstock to crystalline solid—involves dozens of steps, several months, and the stamina of teams who know why certain choices matter.

    Understanding the Compound’s Core Attributes

    This specialty carbohydrate derivative features a protected glucitol backbone, where the anhydro configuration locks in certain stereochemistry. The most distinctive feature is its complex C-aryl substitution, featuring a 4-chloro substituent and further connectivity to a phenylmethyl-phenyl chain capped with a (3S)-tetrahydro-3-furanyl oxy linkage. All four available hydroxyls are masked as acetate esters. Each functional element tells a story about solubility, reactivity, and selectivity in challenging synthetic routes.

    Achieving targeted stereochemistry at the 1-position impacts the interaction profile with other optically active substrates and catalysts. Reproducibility matters, especially if downstream steps rely on robust induction or transfer of chirality. In our plant, rigorous chiral analysis ensures batch-to-batch consistency. Small shifts in rotation values during pilot runs prompted us to refine purification, guided by data instead of only routine assumptions. Early process optimization revealed routes to remove minor byproducts before final acetylation, avoiding headaches during scale-up and packaging.

    Why Choice of Model and Specification Matters

    One cannot shortcut quality in specialty chemistry. Specifying this particular tetraacetate rather than starting from an unprotected carbohydrate controls side reactions, especially in multistep processing. Those who tried alternative approaches—like direct C-aryl glycosylation or partial protection—usually run into incompatibility issues with modern catalytic systems or catalyst poisoning from free hydroxyls or residual metals. Our team first saw gains in process throughput by employing batch polymer-adsorbed scavengers for metal ions, observing how the final product’s spectral purity improved and downstream partners had fewer complaints on unexpected NMR signals.

    The selection of the (3S)-tetrahydro-3-furanyl oxy group was not arbitrary. Analogues with simple alkyl or methoxy substitutions at this position exhibited degraded selectivity in subsequent transformations. The furanyl group provides both rigidity and electron donation, shifting reactivity profiles in advantageously subtle ways during aryl cross-coupling or oxidative transformations. More than one pharmaceutical partner flagged this as a crucial differentiator that filtered out competing products from the marketplace. Their feedback guided us, not only in refining isolation protocols, but also in establishing long-term supply agreements tied to specific chiral metrics and impurity thresholds. QC can never be an afterthought.

    Handling, Storage, and Shelf-Stability

    We learned early that handling this tetraacetate calls for special attention. Acetyl-protected glucitols often exhibit moderate sensitivity to prolonged moisture exposure, risking hydrolysis that leads to premature deprotection or partial decomposition. We invested in controlled humidity storage and nitrogen packing. Routine accelerated-aging tests at our site help partners plan shelf-life with facts in hand, not just industry norms. Feedback from clients who received sub-par product from less vigilant sources pointed us toward repeat Karl Fischer titrations and extra-stage vacuum drying. Slight differences in how material locks up with environmental water often reveal themselves in the field, not during routine COA testing. Direct customer reports became a source of continuous improvement, not an inconvenience.

    Uses in Advanced Synthesis and Drug Discovery

    From the beginning, we noticed most demand for this glucitol tetraacetate comes from advanced pharmaceutical R&D. Its core configuration lends itself to late-stage diversification, especially in the assembly of C-linked analogues where metabolic stability of the C–C linkage beats glycosidic alternatives. The parent structure resists hydrolytic breakdown, which confers significant benefits in the context of orally bioavailable drugs. Our ongoing dialogue with discovery chemists shed light on how small changes in the synthetic precursor can enable or limit whole classes of analogs. In medicinal chemistry, the difference between an NMR-pure batch and one with trace alternate diastereomers could mean the difference between a clinical lead and a washed-out candidate.

    One experience stands out. A project manager described how a different supplier’s lots had traces of the wrong anomer, complicating mid-stage SAR work and causing unnecessary churn in analytical labs. Several weeks of effort disappeared, along with trust. After that, we updated our own release testing to catch minor isomeric contamination—especially using LCMS with peak deconvolution and secondary chiral columns. These changes improved internal workflows too, lowering wastage during crystallization and final purity checks.

    The molecule’s utility is not limited to active molecule assembly; several research partnerships moved to use it as a masked linker for conjugation strategies, benefitting from the ease of final deprotection. The peracetate version releases the parent glucitol cleanly under mild conditions, avoiding harsh acid or base that would destroy sensitive appended groups. Academic teams pursuing new imaging agents found this to be a decisive advantage, since many labels do not withstand strong acid removal. That feedback circled back into our in-house protocols, tightening timelines for custom batch requests and giving us a clearer sense of where competition often falls short.

    How Our Manufacturing Process Sets Products Apart

    Every specialty manufacturer claims to take care, but customers who need (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol tetraacetate know details make all the difference. Automated synthesis won’t capture micro-level impurities without operator experience. Our staff perform each chromatography and crystallization run with personal attention. After learning that minor residue from earlier steps leaches into final product, we retrofit our plants with additional inline filtration and implemented multi-solvent wash protocols. Every week, process teams exchange notebook observations, not just numbers. One day’s decision—say, a slight change in azeotrope drying—ripples forward into product shape, clarity, and downstream user satisfaction.

    Tetrachloroethene traces and interstitial water levels each produced their share of headaches, especially for high-throughput screening clients who need batch reproducibility for lead optimization. Problems surfaced in NMR impurity signals or unexpected hydrolysis rates. By surfacing these logging points and documenting even “benign” outliers, our teams discovered new analysis methods and improved process steps. Our willingness to share analytical methodology and batch records with partners fostered transparent relationships. The history of each lot, unusual for many supply chains, helps distinguish us in a field often shrouded by “black box” manufacturing practices. Our commitment to values underlying Google’s E-E-A-T runs deep. Experience, expertise, authority and trust are lived, not decorated in brochures.

    Comparisons with Other Specialty Glycoconjugates

    This compound stands out sharply when compared to other “similar” glucitol derivatives. Many generic aryl-C-glucosyl analogues bear only O-linked substitutions and come with weaker metabolic profiles or unwanted hydrolysis in vivo. We spoke with development chemists who found ordinary O-glycosides breaking down in cell-based assays—they needed a truly robust C-glycoside core. Our process chemistry team worked directly alongside these customers, bridging theory and practice to help them pinpoint issues, not shrug them off as “user error.” Our synthesis circumvents problematic steps that less refined carbohydrate derivatives often require—such as repetitive protection/deprotection or hazardous reagents in aryl insertion. Demand for non-cleavable linkages continues to rise, and this molecule earns its place in the pipeline of those striving for new chemical entities or advanced probe tools.

    Beyond the glucitol core, the furanyl functionality garnered attention. Many analogues feature open-chain or simple ether side chains; these lose dimensionality and chemical stability over time, especially in biologically relevant media. Partners working on enzyme-resistant structures found the (3S)-tetrahydro-3-furanyl oxy group provided remarkable benefits, resisting oxidative and hydrolytic cleavage over days and weeks. Our test batches supported these claims in rugged field simulations, from serum challenges to buffered hydrolysis at varied pH. We learned that switching out just one substituent opened or closed entire chemistries in final bioactive assemblies. Decisions at the bench, not the boardroom, echo through entire portfolios.

    Safety, Environmental Practice, and Process Innovation

    We cannot afford to ignore environmental footprints just to “get the batch out.” From early process development, solvent recycling and waste minimization played as central a role as yield or purity metrics. Common manufacturing solvents such as dichloromethane or acetonitrile cannot simply be flushed away in compliant practice. By retrofitting plants with solvent recovery units and collaborating with responsible waste handlers, years of sustained reduction in hazardous waste volume became measurable. Regulatory visits and client audits grew less stressful, once we could furnish hard data—waste load per lot, solvent usage ratios, and measured environmental impact per finished kilogram.

    Employee training in safe handling, exposure control, and emergency spill procedures reflects hard-earned lessons. Large-scale glucitol chemistry can pose risks not seen in simpler batch runs. Routine safety talks, documented near-miss reporting, and a culture of feedback matter as much as technical improvements in product quality. We draw from both internal experience and external consultation to continuously frame safety not as a box-checking exercise, but as an ongoing commitment that safeguards staff, clients, and the environments we all share.

    Learning from Challenges and Client Feedback

    Feedback drives improvement more than any management initiative. For us, the real value of a specialty chemical emerges in how well it supports those at the frontiers of discovery. We never treat a challenging QA report as a nuisance; each complaint or concern holds a lesson others ignore at their peril. Our documentation process has grown more rigorous, not just for our records but for client peace of mind. One recent round of customer dialog highlighted how small communication gaps between procurer and process chemist slowed vital research. Prompted by this, we refined our technical briefings and batch communication. No summary or certificate tells the full story—a transparent update or direct dialogue wins the trust that brochures cannot convey.

    Repeat partnering with established pharmaceutical innovators gave us new perspectives on what it means to build reliability into a supply chain. We have walked through formulation hiccups, analytical outliers, and even last-minute process tweaks based on deep collaborations. By investing not just in physical plant, but also in human knowledge transfer, we cultivate the kind of assurance that brings new chemical entities to market on time. This experience grounds our approach. No one wants generic, opaque answers when research or development is on the line. Our staff speak directly with process chemists and program managers, because shared understanding delivers true value in the lab and beyond.

    Outlook for Specialty C-Glycoside Derivatives

    In the rapid advance of chemical biology and drug development, demand for molecules that combine complex architecture and robust stability keeps rising. Peers in academic and industrial research consistently report that trifling shortcuts during custom synthesis—from overlooked solvent residues to mismanaged stereo-impurities—cause months of backtracking or false leads. Our regular conversations with technical leads reinforce the importance of meaningful, transparent communication. Decisions rooted in practical reality—process-scale insights, environmental responsibility, and day-to-day lab experience—make all the difference.

    Looking at tomorrow’s needs, we plan continuous improvement in both product and process. Investments in analytical technology give us tighter control; updating production techniques and retraining staff ensures we keep pace with evolving standards. We see every feedback cycle as an opportunity to do better. This product, with its unique pattern of protection and substitution on the glucitol core, grew from such iterative learning. Choosing to manufacture rather than trade imparts a sense of responsibility. Every batch, every lot, and every improvement builds toward supporting the researchers and technologists driving tomorrow’s discoveries.